MINNEAPOLIS, July 20, 2020 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH) today announced the expansion of the
RNAscope™ platform with the release of the miRNAscope™ Assay. The
RNAscope technology is an advanced in situ hybridization assay for
the spatial visualization of single-molecule RNA with single-cell
resolution directly in intact tissues.
The miRNAscope Assay extends the RNAscope technology to enable
the in situ detection of short nucleic acid targets between 17-50
nucleotides which includes an important class of small non-coding
RNAs called microRNAs as well as short synthetic oligonucleotide
therapeutics such as small interfering RNAs (siRNAs) and antisense
oligonucleotides (ASOs). The assay addresses a critical need to
reliably detect these ultra-short molecules in native tissue with
minimal time and effort, delivering data in an easy to interpret
format. Traditional assays such as microarrays, PCRs, and
sequencing methods provide useful molecular profiles, but their use
with dissociated cells result in the loss of clinically relevant
tissue morphological information. The miRNAscope assay utilizes
Bio-Techne's patented signal amplification and background
suppression technology to deliver researchers with comparatively
elevated specificity and sensitivity as well as high
signal-to-noise detection. Utilization of this assay enables
researchers to perform experiments for various applications such as
identifying specific cellular subtypes, visualizing gene
regulation, and evaluating therapeutic ASO or siRNA delivery,
biodistribution, cellular uptake, and persistence over time, all
without compromising the morphological features of the tissue in
question.
After obtaining the first data from this technology through the
Early Technology Access program, a leading BioPharma
Company commented, "We had a great experience using
miRNAscope in our compound screening efforts. The technique is
incredibly specific, and the results are very easy to understand.
Also, working with Bio-Techne's ACD team has been extremely
beneficial. They communicated with us during the process to ensure
we can get the answers to our questions. They generated impeccable
tissue staining!"
Kim Kelderman, President of
Bio-Techne's Diagnostics and Genomics Segment, commented, "We are
excited to expand our in situ RNA tissue analysis leadership
position with the release of the miRNAscope™ Assay. MicroRNAs are
an important class of regulatory non-coding RNAs that are gaining
more interest from companies in the diagnostic and therapeutic
space. In addition, there is an increasing investment level to
develop short oligonucleotide-based drugs. Our aim is to provide
researchers with a platform to easily and reliably detect these
small RNAs and oligonucleotides with single-cell and subcellular
resolution in a complex and heterogeneous tissue environment."
The miRNAscope Assay kit from Bio-Techne is
intended for research use only. To learn more, visit:
https://acdbio.com/mirnascope-assay-red-overview
About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Senior
Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-techne-announces-commercial-release-of-new-assay-for-detecting-asos-mirnas-and-sirnas-in-tissue-301095337.html
SOURCE Bio-Techne Corporation